Masimo has expressed satisfaction with the reinstatement of the import ban on Apple Watch sales in the United States. This action came about due to the discovery that Apple’s smartwatch had violated a Masimo patent related to its pulse oximetry technology.
Initially, the sale of Apple’s smartwatches was halted on December 21, but a temporary stay was granted a week later, allowing Apple to resume selling the product for a brief period. In an attempt to work around the reinstated ban, Apple has chosen to market its Apple Watch Series 9 and Ultra 2 devices without the SpO2 monitoring feature.
Masimo, renowned for its medical technology, has integrated its pulse oximetry module into the W1 Sport wearable and intends to do the same for the forthcoming Freedom model, which was showcased at CES 2024. The company recently unveiled a new promotion for its latest gadget, offering a $500 credit towards the purchase of the Masimo Freedom watch when you buy the Masimo W1 health watch.
To redeem this credit, customers must do so before December 31st or within 30 days of the Freedom watch’s launch, whichever is later.
The Freedom model, first introduced in March 2023, is available in two variations: the Smart Health Watch and the Band. It builds upon the health-tracking capabilities of the W1, including monitoring blood oxygen levels, pulse rates, respiration rates, and hydration indexes.
It’s important to note that the W1 has received FDA clearance for its medical-grade pulse oximetry sensor, a distinction the Apple Watch lacks. The new Freedom model is currently awaiting approval. Additionally, the new wearables offer sleep and activity tracking, with additional insights accessible through an accompanying app.
The anticipated retail price for the Masimo Freedom smartwatch is $999, though the exact launch date remains uncertain, with rumors suggesting it may arrive before the year’s end. Early reservations for the smartwatch also qualify for a $100 discount.